Kidney Week

Abstract: TH-PO654

Incidence of Adverse Events from SARS-CoV-2 Vaccination and Its Potential Effect on the Outcome of Lupus Nephritis

Session Information

• Lupus Nephritis: Clinical, Outcomes, and Therapeutics
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Angeliki Sardeli, MD

• Marinaki, Smaragdi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Greece

Smaragdi Marinaki, MD

• Flouda, Sofia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Sofia Flouda

• Pelagia, Kriki, Panepistemiako Geniko Nosokomeio Alexandroupoles, Alexandroupoli, Eastern Macedonia and Thr, Greece

Kriki Pelagia

• Venetsanopoulou, Aliki I., Panepistemio Ioanninon Reumatologike Klinike, Ioannina, Epirus, Greece

Aliki I. Venetsanopoulou, PhD

• Pantzopoulou, Evangelia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Evangelia Pantzopoulou, MD

• Panagoutsos, Stylianos A., Panepistemiako Geniko Nosokomeio Alexandroupoles, Alexandroupoli, Eastern Macedonia and Thr, Greece

Stylianos A. Panagoutsos, MD

• Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Sophia Lionaki, MD, PhD

Background

To investigate the incidence of adverse events associated with SARS-CoV-2 vaccination in patients with lupus nephritis (LN).

Methods

Patients with biopsy-proven LN, who were vaccinated against SARS-CoV-2, were retrospectively studied. Patients who reached ESKD prior to vaccination were excluded. Histopathological class of LN, immunosuppressive regimens for LN, outcome of LN as a result of treatment, the time interval form the diagnostic biopsy to vaccination, the number of vaccine doses, adverse events associated with the vaccine, including systemic and local adverse events were recorded. We also explored the potential of LN relapse after vaccination among patients in remission.

Results

Ninety patients with SLE and renal involvement were included with age of 31(±18) years, of whom 80% were women. Proliferative LN was present in the diagnostic kidney biopsy in 68(77.2%) cases and 91.8% of patients had achieved remission with treatment prior to vaccination. 86.7% of patients were vaccinated with 3(2.75, 3) doses. The median time from diagnosis to vaccination was 59(32-137) months and 70.5% of patients were on immunosuppression at vaccination. 30.5% of patients reported systemic and 36.1% local adverse reactions at the site of administration. Among patients in remission, who were vaccinated, only 1(1.2%) experienced a relapse of LN within 3 weeks of the 1^st dose. Three (3.4%) patients who had treatment-resistant disease experienced a worsening of SLE activity after vaccine administration.

Conclusion

In this cohort of patients with a history of LN, SARS-CoV-2 vaccination appears safe, with no effect on the likelihood of disease recurrence among patients who have achieved remission.